Giuseppe Curigliano

Board Member, European Cancer Organisation
Professor of Medical Oncology, University of Milan
Chief of the Division of Early Drug Development, European Institute of Oncology, Italy

Giuseppe Curigliano, MD PhD, is Full Professor of Medical Oncology at the University of Milano and Chief of the Clinical Division of Early Drug Development at European Institute of Oncology, Milano, Italy.

Dr. Curigliano is an expert in the field of advanced drug development in solid tumors, with specific interest on breast cancer. He contributed to the development of many anticancer treatments actually available as standard of care in the treatment of multiple solid tumors. Since 2001 he is tenure-track and full-time
cancer specialist at European Institute of Oncology – one of the world’s leading cancer-research institutes and the premier Cancer Center in Italy, third in Europe and 12th globally. He serves as member of the Italian Higher Health Council. Dr. Curigliano serves ESMO as Chair of the Clinical Practice Guidelines Committee. He is member of EUSOMA Executive Committee serving as President-Elect. He was awarded with the first ESO Umberto Veronesi Award in Vienna in 2017 and with the Fellowship of the European Academy of Cancer Sciences in Paris in 2017. Dr Curigliano in 2022 was identified as Clarivate™ world’s most influential researchers. Dr Curigliano has contributed to over 670 peer-reviewed publications.

Updated: January 2024